Despite the recent launch of congenital adrenal hyperplasia (CAH) drug Crenessity, Neurocrine Biosciences' disappointing ...

SAN DIEGO, Feb. 10, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX) today announced that on February 10, 2025, the Compensation ...

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on February 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified ...

TD Cowen began coverage of Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Buy rating, citing the company's strong position in ...

BridgeBio Pharma (NASDAQ:BBIO – Get Free Report) is expected to issue its quarterly earnings data on Thursday, February 20th. Analysts expect the company to announce earnings of ($0.82) per share and ...

Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) was upgraded by equities researchers at StockNews.com from a “buy” rating to a “strong-buy” rating in a research report issued on Monday. A ...

Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) stock has reached a 52-week low, trading at $35.47, with InvestingPro technical indicators showing oversold conditions. The stock has declined sharply, ...

Congenital adrenal hyperplasia (CAH) is a monogenic autosomal recessive disorder and more than 150 mutations of the CYP21A2 gene have been already reported and based on the degree of the enzymatic ...

Other symptoms of PCOS include: Nonclassic congenital adrenal hyperplasia (NCCAH) is a genetic disorder. The late-onset form has similar symptoms to PCOS. It is due to a missing enzyme responsible for ...

To access the free health screening, people only need to register through the SATUSEHAT Mobile (SSM) application. Following ...

The Janus Henderson Global Life Sciences Fund returned -11.16% and the MSCI World Health Care IndexSM returned -11.40%. Click ...